The clinical, personal and societal impact imposed by rheumatoid arthritis (RA) has transformed in the last decade. The likelihood is increasing of a more favourable disease course, associated with less articular damage and better long‐term prognosis in RA (1, 2). This has been driven largely by a substantially revised treatment paradigm, comprising earlier diagnosis, treatment and application of treat‐to‐target strategies, together with the advent of selective immune‐targeted therapeutics based upon pathogenesis driven principles.
No takes yet. Share an insight, caveat, or question.
Fragoulis et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: